PCM
NKTR icon

Prelude Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Prelude Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7
Closed -$4K – 1932
2019
Q2 		$4K Buy
+7
New +$3.51K ﹤0.01% 1539
2014
Q3 		– Sell
-213
Closed -$41K – 2038
2014
Q2 		$41K Buy
+213
New +$37.7K 0.01% 1451

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's NKTR Position: Q2 2025 in Review

Prelude Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 44,677 shares — an estimated $456K sold.

Prelude Capital Management first reported a position in NKTR in Q2 2013 and held it in 25 quarters. The position peaked at $893K in Q2 2017. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Prelude Capital Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 44,677 Nektar Therapeutics shares in Q2 2025, an estimated $456K.
  • Prelude Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 25 quarters.
  • Prelude Capital Management's Nektar Therapeutics position peaked at $893K in Q2 2017.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.